HIF1A and non-small cell lung carcinoma: Our study found that after SIRT6 was overexpressed in erlotinib-sensitive NSCLC cells, the levels of HIF-1α and the glycolytic rate-limiting enzyme HK2 also increased (Fig. 6A).